Option chain shows key data for Xenetic Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Xenetic Biosciences.

Xenetic Biosciences (NASDAQ:XBIO) Stock, Option Chain

Xenetic Biosciences

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.

Earnings

Earnings Misses

News

Penny Stocks

Markets

Trading Ideas

AFMD

XBIO

Xenetic Biosciences (NASDAQ: XBIO) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.

Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates

Analyst Color

Biotech

Downgrades

Health Care

Analyst Ratings

General

Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences

Small Cap

Intraday Update

Movers

ACHR

ALGS

ANTE

ATNX

AUTL

BBLN

BLBD

CRVS

DBVT

DRMA

DRTT

EAST

EFSH

GLDD

GLMD

HCDI

IBRX

IMPL

JAGX

JWAC

LMFA

Larimar Therapeutics, Inc. - Common Stock

LRMR

MGOL

MIND

MNDY

NGMS

NSPR

OCUP

ORMP

OSUR

PRSO

SANA

SBFM

SRPT

SWIM

THCH

TIVC

TTCF

TWST

VERO

WISA

WLDS

XELA

ZAPP

ZKIN

Gainers


	NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.


Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

XBiotech Inc

First-of-its-kind cooling solution integrates air and liquid cooling technologies to meet the evolving and mixed cooling needs of data centers supporting AI
Data center operators face the challenge of supporting rapidly evolving environments in which established IT applications increasingly co-exist alongside the high-density computing being deployed to support AI. <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vertiv.com%2Fen-us%2F&amp;esheet=54153983&amp;newsitemid=20241117945678&amp;lan=en-US&amp;anchor=Vertiv&amp;index=1&amp;md5=edc7f33a3565b42afb7a1e7fa352012c">Vertiv</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>), a global provider of critical digital infrastructure and continuity solutions, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.compassdatacenters.com%2F&amp;esheet=54153983&amp;newsitemid=20241117945678&amp;lan=en-US&amp;anchor=Compass+Datacenters&amp;index=2&amp;md5=0910a054cbe1ff4cf595019ca8941c60">Compass Datacenters</a>, which designs, builds and operates data center campuses for some of the world's largest technology companies, announced today they have collaborated to develop a first-of-its-kind solution that enables future deployments of AI with the ability to flex between air and liquid cooling to support high-density computing. Vertiv and Compass engineers collaborated on this vision for a future-forward cooling solution, with Vertiv developing and manufacturing the technology solution. The initial units will be deployed at a Compass facility in 1Q 2025 as part of a planned multi-year, multi-billion dollar supply arrangement.

Vertiv And Compass Datacenters Collaborate On Combination Liquid And Air Cooling System To Accelerate Deployment Of Liquid Cooling For AI Applications

Analysis Suggests Harmonic, Which Trades at ~$12, Can Drive Share Price Appreciation by Meeting 2026 Broadband Targets or Through a Sale Process That Could Deliver ~$20 Per Share
Contends There is a Clear Opportunity for Harmonic to Attract Interest from Well-Capitalized Acquirers, Such as Ciena Corporation
Fears Management's Poor Investor Communication Has Caused Harmonic to Trade at a Depressed Multiple Despite Strong Financials, Best-in-Class Products and Market-Leading Innovation
Urges Harmonic's Refreshed Board to Evaluate Company's Standalone Prospects Versus Viable Sale Options
Ancora Holdings Group, LLC (collectively with its affiliates, "Ancora"), a significant shareholder of Harmonic, Inc. ("Harmonic" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>), today released a presentation detailing what it believes is an opportunity for significant near-term value creation: "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fancoraharmonic.s3.us-east-2.amazonaws.com%2FThe%2BUnrealized%2BValue%2BCreation%2BOpportunity%2Bat%2BHarmonic.pdf&amp;esheet=54154115&amp;newsitemid=20241118401341&amp;lan=en-US&amp;anchor=The+Unrealized+Value+Creation+Opportunity+at+Harmonic&amp;index=1&amp;md5=c3ce1ccbce6cea9808e8252e29b22385">The Unrealized Value Creation Opportunity at Harmonic</a>." Ancora plans to engage in a constructive and open dialogue with Harmonic to gauge the Board of Directors' willingness to evaluate the Company's standalone prospects versus a potentially value-maximizing sale to one of the many logical acquirers in the space. To ensure Harmonic's leadership understands all shareholders' views following a period of disappointing results, we hope our fellow investors provide feedback as soon as possible and well ahead of the Company filing its proxy statement for the 2025 Annual Meeting of Shareholders. We consider Harmonic to be a great underlying business, but believe the Company does not have infinite time to achieve its full potential.

Management

HLIT

Ancora Releases Presentation Highlighting The Opportunity For Significant Near-Term Value Creation At Harmonic; Says "Analysis Suggests Harmonic, Which Trades At ~$12, Can Drive Share Price Appreciation By Meeting 2026 Broadband Targets Or Through A Sale Process That Could Deliver ~$20 Per Share"

Barclays analyst Brendan Lynch maintains Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) with a Overweight and lowers the price target from $133 to $131.

Price Target

Barclays Maintains Overweight on Iron Mountain, Lowers Price Target to $131

RVSN

Rail Vision Launches Semi-Autonomous Active Control System For U.S. Fleet Rollout By Year-End 2024

FOUR

San Antonio Spurs Partners With Shift4 To Enhance Payment Technology

Hovde Group analyst Brett Rabatin downgrades FB Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBK#NYSE">FBK</a>) from Outperform to Market Perform and announces $60 price target.

Hovde Group Downgrades FB Financial to Market Perform, Announces $60 Price Target

Raymond James analyst Adam Tindle initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Outperform rating and announces Price Target of $28.

Initiation

INGM

Raymond James Initiates Coverage On Ingram Micro Holding with Outperform Rating, Announces Price Target of $28

Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) reported quarterly losses of $(0.05) per share. This is a 66.67 percent increase over losses of $(0.15) per share from the same period last year. The company reported $40.27 million in sales this quarter. This is a 1.00K percent increase over sales of $3.65 million the same period last year.

SOAR

Volato Group Q3 EPS $(0.05) Up From $(0.15) YoY, Sales $40.27M Up From $3.65M YoY

Shares of Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) experienced a significant rise of 13.94% during pre-market trading on Monday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge comes as the company faces potential delisting from the Nasdaq Stock Market.
What Happened: Super Micro is preparing to submit a proposal to Nasdaq to avoid delisting. The company, which has seen considerable success due to the AI boom, is under scrutiny regarding its operations. The proposal is expected to be submitted by Monday, aiming to maintain its trading status on the exchange, Barron's <a href="https://pro.benzinga.com/dashboard">reported</a> on Monday.
The delisting threat arises from concerns over the company&#8217;s operations, despite its recent achievements in the artificial intelligence sector. By taking proactive steps, Super Micro hopes to avert the delisting risk and continue benefiting from the AI industry&#8217;s growth.
See Also: <a href="https://www.benzinga.com/24/11/42022585/michael-van-de-poppe-says-bitcoin-ethereum-and-altcoins-close-to-the-point-where-investors-can-buy-the-dip?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michael Van De Poppe Says Bitcoin, Ethereum And Altcoins Close To The Point Where Investors Can &#8216;Buy The Dip&#8217;</a>
Why It Matters: The potential delisting of Super Micro is linked to serious issues, including the resignation of its auditor, Ernst &amp; Young, amid allegations of accounting irregularities and possible export control violations. <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41850890/super-micro-delisting-risk-puts-1-7-billion-bond-repayment-on-the-line">Delisting could trigger</a> an early repayment of up to $1.725 billion in bonds, posing a significant financial challenge for the company.
Furthermore, Super Micro is approaching a critical Nasdaq deadline, with its future potentially hinging on the<a href="https://www.benzinga.com/tech/24/11/42008585/why-super-micros-survival-may-hinge-on-nvidia-earnings-nasdaq-deadline"> upcoming earnings report</a> from Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). The server manufacturer, once a key player in Nvidia&#8217;s AI-driven success, now faces uncertainty as it navigates these challenges. The outcome of Nvidia&#8217;s earnings could provide insight into whether Super Micro can stabilize its situation or face further difficulties. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42025317/dogecoin-repeating-its-historical-pattern-says-analyst-meme-coin-set-to-touch-3-by-trumps-inauguration-day-2025?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin &#8216;Repeating Its Historical Pattern,&#8217; Says Analyst: Meme Coin Set To Touch $3 By Trump&#8217;s Inauguration Day 2025</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

NVDA

SMCI

Super Micro Computer Surges In Monday Pre-Market Amid Delisting Concerns: What's Happening?

Barclays analyst Anthony Powell maintains First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Equal-Weight and lowers the price target from $56 to $55.

Barclays Maintains Equal-Weight on First Industrial Realty, Lowers Price Target to $55

News Summary
<ul>
<li>AI infrastructure additions, including new liquid and air-cooled Dell PowerEdge XE servers and Dell Data Lakehouse enhancements, efficiently deliver advanced compute at scale and simplify data access for AI</li>
<li>Supporting the NVIDIA GB200 Grace Blackwell NVL4 Superchip will be a new Dell PowerEdge XE server designed for the Dell IR7000, supporting up to 144 GPUs in a 50OU standard rack</li>
<li>New solutions accelerate the development and deployment of AI applications</li>
<li>Dell Professional Services for sustainability, data management and networking help organizations more quickly reach AI goals by reducing complexity</li>
</ul>

DELL

Dell Technologies Boosts AI For Enterprises With Dell AI Factory Advancements; New AI Infrastructure, Solutions And Services Improve Performance And Accelerate Time To Value For AI Projects, While Helping Organizations Better Manage Data And Improve Efficiency

Hovde Group analyst Brett Rabatin downgrades National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) from Outperform to Market Perform and announces $55 price target.

NBHC

Hovde Group Downgrades National Bank Holdings to Market Perform, Announces $55 Price Target

Barclays analyst Tim Long maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Equal-Weight and raises the price target from $810 to $822.

EQIX

Barclays Maintains Equal-Weight on Equinix, Raises Price Target to $822

Raymond James analyst Simon Leopold upgrades Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) from Outperform to Strong Buy and raises the price target from $23 to $29.

Upgrades

Raymond James Upgrades Hewlett Packard to Strong Buy, Raises Price Target to $29

Contracts

BOSC

BOS Better Online Solutions Announces Its Supply Chain Division Has Received A $2.7M Order From A Subcontractor Of One Of Its Primary Customers In The Defense Sector; Order Is For Delivery Gradually By May 2025

Barclays analyst Manav Patnaik maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Overweight and raises the price target from $260 to $300.

Barclays Maintains Overweight on Ecolab, Raises Price Target to $300

ATCH

AtlasClear Holdings Q1 EPS $0.00 Up From $(0.03) YoY Revenue $2.804M Up From $0.00 YoY

IBM To Deploy AMD Instinct MI300X Accelerators On IBM Cloud

Insider Trades

TOST

Reported November 15: ValueAct 13F Shows New Position In Toast With 15,482,200 Shares

Barclays analyst John Coffey maintains DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) with a Equal-Weight and raises the price target from $8 to $9.

Barclays Maintains Equal-Weight on DLocal, Raises Price Target to $9

Xenetic Biosciences appoints James Parslow as interim CEO

An announcement from Xenetic Biosciences (XBIO) is now available. Xenetic Biosciences, Inc. has elevated their CFO, James F. Parslow, to Interim CE...

Xenetic Biosciences Announces Executive Leadership Restructuring

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Xenetic Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/xbio-stock-quote/">XBIO</a>) just reported results for the second quarter of 2024.<ul><li>Xenetic Biosciences reported earnings per share of -83 cents. This met the analyst estimate for EPS of -83 cents.</li><li>The company reported revenue of $726,404.</li><li>This was 34.52% better than the analyst estimate for revenue of $540,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xbio-stock-earnings-xenetic-biosciences-for-q2-of-2024/">XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Hold rating on Xenetic Biosciences (XBIO – Research Report). The com...

H.C. Wainwright Sticks to Their Hold Rating for Xenetic Biosciences (XBIO)

The company may offer, issue and sell, from time to time, shares of its common stock, preferred stock, warrants, units, rights, depositary shares a...

Xenetic files $50M mixed securities shelf

Xenetic Biosciences files for $50M mixed securities shelf

Xenetic Biosciences ( ($XBIO) ) just unveiled an update. Xenetic Biosciences has extended its collaboration with The Scripps Research Institute to ...

Xenetic Biosciences Expands Collaboration for Cancer Treatment

Analysts fell to the sidelines weighing in on Xenetic Biosciences (XBIO – Research Report) and CytomX Therapeutics (CTMX – Research Report) with ne...

Wall Street Analysts Are Neutral on Top Healthcare Picks

Xenetic (XBIO) Biosciences announced the presentation of positive preclinical data. The poster titled, " DNase I Targeting of Neutrophil Extracellu...

Xenetic presents preclinical data on DNase platform technology

Xenetic Biosciences GAAP EPS of -$0.28, revenue of $614.1M

CTMX

Press Releases

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Events

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Comments

Xenetic Biosciences

Xenetic Biosciences (XBIO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga